BioCryst Pharmaceuticals 관리

관리 기준 확인 3/4

BioCryst Pharmaceuticals CEO는 Jon Stonehouse, Jan2007 에 임명되었습니다 의 임기는 18.08 년입니다. 총 연간 보상은 $ 4.78M, 13.9% 로 구성됩니다. 13.9% 급여 및 86.1% 보너스(회사 주식 및 옵션 포함). 는 € 7.80M 가치에 해당하는 회사 주식의 0.45% 직접 소유합니다. 7.80M. 경영진과 이사회의 평균 재임 기간은 각각 5 년과 5.5 년입니다.

주요 정보

Jon Stonehouse

최고 경영자

US$4.8m

총 보상

CEO 급여 비율	13.9%
CEO 임기	18.1yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	5yrs
이사회 평균 재임 기간	5.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Jon Stonehouse 의 보수는 BioCryst Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$124m
Jun 30 2024	n/a	n/a	-US$146m
Mar 31 2024	n/a	n/a	-US$209m
Dec 31 2023	US$5m	US$666k	-US$227m
Sep 30 2023	n/a	n/a	-US$236m
Jun 30 2023	n/a	n/a	-US$243m
Mar 31 2023	n/a	n/a	-US$226m
Dec 31 2022	US$7m	US$640k	-US$247m
Sep 30 2022	n/a	n/a	-US$193m
Jun 30 2022	n/a	n/a	-US$210m
Mar 31 2022	n/a	n/a	-US$194m
Dec 31 2021	US$7m	US$583k	-US$184m
Sep 30 2021	n/a	n/a	-US$227m
Jun 30 2021	n/a	n/a	-US$214m
Mar 31 2021	n/a	n/a	-US$209m
Dec 31 2020	US$6m	US$567k	-US$183m
Sep 30 2020	n/a	n/a	-US$125m
Jun 30 2020	n/a	n/a	-US$116m
Mar 31 2020	n/a	n/a	-US$115m
Dec 31 2019	US$2m	US$550k	-US$109m
Sep 30 2019	n/a	n/a	-US$134m
Jun 30 2019	n/a	n/a	-US$126m
Mar 31 2019	n/a	n/a	-US$107m
Dec 31 2018	US$4m	US$550k	-US$101m

보상 대 시장: Jon 의 총 보상 ($USD 4.78M )은 German 시장( $USD 1.48M ).

보상과 수익: Jon 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jon Stonehouse (63 yo)

18.1yrs

테뉴어

US$4,777,778

보상

Mr. Jon P. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co. Ltd. since joining in January 8, 2007 and also has been its President s...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jon Stonehouse	CEO, President & Executive Director	18.1yrs	US$4.78m	0.45% € 7.8m
Anthony Doyle	Senior VP	4.8yrs	US$1.79m	0.055% € 940.9k
Alane Barnes	Senior VP	18.4yrs	US$1.93m	0.10% € 1.8m
Helen Thackray	Chief Research & Development Officer	3.9yrs	US$2.39m	0.070% € 1.2m
Charles Gayer	Senior VP & Chief Commercial Officer	5.1yrs	US$1.74m	0.11% € 2.0m
John Bluth	Chief Communications Officer	no data	데이터 없음	데이터 없음
Stephanie Angelini	Chief People Officer	no data	데이터 없음	데이터 없음
William Sheridan	Chief Development Officer	16.6yrs	US$2.66m	데이터 없음
Yarlagadda Babu	Chief Discovery Officer	11.3yrs	US$2.57m	데이터 없음
Jinky Rosselli	Chief Data & Insights Officer	3.3yrs	데이터 없음	데이터 없음
Philip George	Chief Strategy Officer	2.4yrs	데이터 없음	데이터 없음
Clayton Fletcher	Chief Business Development Officer	2.1yrs	데이터 없음	데이터 없음

5.0yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: BO1 의 관리팀은 경험 ( 5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jon Stonehouse	CEO, President & Executive Director	18.1yrs	US$4.78m	0.45% € 7.8m
Vincent Milano	Independent Director	3.6yrs	US$434.82k	0.033% € 576.6k
Stephen Aselage	Independent Director	6.1yrs	US$446.90k	0.024% € 408.7k
Alan Levin	Independent Director	5yrs	US$434.54k	0.014% € 234.8k
George Abercrombie	Independent Director	13.3yrs	US$432.74k	0.0062% € 107.1k
Theresa Heggie	Independent Director	6.2yrs	US$433.57k	0.022% € 383.1k
Nancy Hutson	Independent Chair	13.1yrs	US$470.30k	0.039% € 664.4k
Steven K. Galson	Independent Director	3.4yrs	US$424.40k	0.017% € 289.7k
A. Sanders	Independent Director	3yrs	US$423.15k	0.010% € 174.2k
Amy McKee	Independent Director	3.4yrs	US$422.32k	0.010% € 174.8k

5.5yrs

평균 재임 기간

63.5yo

평균 연령

경험이 풍부한 이사회: BO1 의 이사회는 경험(평균 재직 기간 5.5 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/02/11 04:01
장 마감 주가	2025/02/11 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

BioCryst Pharmaceuticals, Inc. 30 애널리스트 중 9 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Huidong Wang	Barclays
Tazeen Ahmad	BofA Global Research
Dae Gon Ha	BTIG

BioCryst Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Insufficient new directors

Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer

Senior VP recently bought €187k worth of stock

BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023

Biocryst Pharmaceuticals, Inc. Announces Executive Changes

Recent updates

BioCryst Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 24, 2025

BioCryst Pharmaceuticals, Inc. Provides Preliminary Unaudited Total Revenue Guidance for the Fourth Quarter and Year 2024 and Year 2025

BioCryst Pharmaceuticals, Inc. Launches ORLADEYO® (berotralstat) in Ireland

New minor risk - Share price stability

BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026

Third quarter 2024 earnings released: US$0.068 loss per share (vs US$0.19 loss in 3Q 2023)

BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat)

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

Insufficient new directors

BioCryst Pharmaceuticals, Inc. Announces Successfully Completed Negotiations with the Pan-Canadian Pharmaceutical Alliance (Pcpa) for Oral, Once-Daily Prorladeyo® (Berotralstat)

Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer

Second quarter 2024 earnings released: US$0.061 loss per share (vs US$0.40 loss in 2Q 2023)

BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 05, 2024

New major risk - Share price stability

Senior VP recently bought €187k worth of stock

BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.28 loss in 1Q 2023)

BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

BioCryst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 06, 2024

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Full year 2023 earnings released: US$1.18 loss per share (vs US$1.33 loss in FY 2022)

BioCryst Launches Orladeyo (Berotralstat) in Italy

BioCryst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 26, 2024

Forecast breakeven date pushed back to 2026

BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat)

New major risk - Share price stability

Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023

Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina

BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO

BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat)

New minor risk - Shareholder dilution

No longer forecast to breakeven

BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2023

No longer forecast to breakeven

BioCryst Pharmaceuticals, Inc. to Present New ORLADEYO®? (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

Biocryst Pharmaceuticals, Inc. Begins Enrollment in Proof-Of-Concept Trial to Confirm Safe, Effective, Once-Daily Dose of Oral Factor D Inhibitor, Bcx10013

BioCryst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

Second quarter 2023 earnings released: US$0.40 loss per share (vs US$0.32 loss in 2Q 2022)

BioCryst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Biocryst Pharmaceuticals, Inc. Announces Executive Changes

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.40 loss in 1Q 2022)

Full year 2022 earnings released: US$1.33 loss per share (vs US$1.03 loss in FY 2021)

BioCryst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 21, 2023

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating Orladeyo(R) (Berotralstat) in Pediatric Patients with Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

Forecast to breakeven in 2025

BioCryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) by the Israeli Ministry of Health

High number of new directors

Biocryst Presents Real-World Data Showing Rapid and Sustained Hae Attack Rate Reduction After Beginning Orladeyo® (Berotralstat), Regardless of Prior Prophylactic Therapy

Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.33 loss in 3Q 2021)

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

BioCryst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

BioCryst Pharmaceuticals, Inc. Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold as Chief Medical Officer

FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

Biocryst Presents Data Demonstrating >99% Suppression of Alternative Pathway Complement Activity with Bcx9930 in C3g Patients

Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) in Saudi Arabia

BioCryst Pharmaceuticals, Inc. Resumes Enrollment in BCX9930 Clinical Program

Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.24 loss in 2Q 2021)

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

BioCryst Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

BioCryst Pharmaceuticals, Inc. Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)